Examining the Patient Experience of Pharmacogenomic Testing Grant uri icon

abstract

  • Examining the Patient Experience of Pharmacogenomic Testing Grant Submission: Genopath, Inc. Background Information / Rationale Pharmacogenomics has emerged as a mechanism for the future of individualized medication management. Cardiology applications have become a prominent area of investigation due to the pathways related to anti-platelet therapy, statins, and beta-blockers. Inter-patient variability to drug dosing is well known, and genetic information is likely a critical missing component. The clinical implication is that tailored medications matched to genetic profiles will provide optimal drug effects and diminished side effects. The initial research on patient centric experience with testing has been equivocal with significant pros and cons being considered by patients. The current study will provide specific patient market analysis about perceptions of value and barriers to acceptance of pharmacogenomic testing. These results will allow for more specific design of patient education materials and clinic ?talking points? for clinicians about the value and challenge of pharmacogenomics testing. Further, the current study will examine the collateral positive effects of pharmacogenomic testing on self care and disease management and potentially describe extended benefits pharmacogenomic testing. A retrospective survey methodology will be employed in this study. We plan to survey approximately 500 patients who have participated in pharmacogenomic testing in medical settings in Huntsville, AL and Harrisburg, PA. The inclusion/exclusion criteria includes the ability to read and write and to provide informed consent. A mail survey method will be used and no patient monetary reward is planned.

date/time interval

  • May 2014 - May 2015